Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

XenoPort Sinks as Spasticity Drug For MS Fails in Trial

Don't Miss Out —
Follow us on:

May 20 (Bloomberg) -- XenoPort Inc., the maker of the drug Horizant for Restless Legs Syndrome, sank the most in almost three years after an experimental medicine failed to meet goals of a late-stage clinical trial.

XenoPort dropped 15 percent to $5.72 at the close in New York, the biggest single-day decline since July 2010. The shares of the Santa Clara, California-based company have declined 26 percent this year.

XenoPort is stopping development of arbaclofen placarbil, an experimental treatment for spasticity in multiple sclerosis patients, after the therapy didn’t help more than placebo, the company said in a statement today. Brian Abrahams, an analyst with Wells Fargo, had estimated sales of $77 million by 2017 for the drug.

“This is disappointing, given promising phase 2 data,” Abrahams wrote in a research note today. “The failure does remove a potential floor in valuation.”

To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.